Summit Therapeutics Inc. Stock

Stocks

SMMT

US86627T1088

Biotechnology & Medical Research

Real-time Estimate 05:47:32 13/10/26 am AEDT 5-day change 1st Jan Change
17.32 USD -1.56% Intraday chart for Summit Therapeutics Inc. +0.32% -0.94%

Valuation: Summit Therapeutics Inc.

Market Cap 10.63B 14.04B 12.57B 11.72B 20.05B 1,343B 20.18B 141B 55.14B 693B 52.76B 51.59B 2,229B P/E 2026 *
-15.2x
P/E 2027 * -15.1x
Enterprise Value 10.16B 13.42B 12.02B 11.2B 19.16B 1,283B 19.28B 135B 52.7B 662B 50.42B 49.31B 2,131B EV / Sales 2026 *
3,462x
EV / Sales 2027 * 249x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
22/09 Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026 CI
15/09 Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients CI
15/09 Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit MT
10/09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
09/09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
26/08 Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release MT
26/08 US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results MT
26/08 Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints MT
26/08 Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer CI
25/08 Wall Street Wants Receipts Zonebourse
25/08 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
12/08 Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC MT
12/08 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
1 day-1.62%
1 week+0.32%
Current month+2.45%
1 month-5.94%
3 months+13.24%
6 months-13.50%
Current year-0.94%
1 week 16.53
Extreme 16.53
18.33
1 month 15.18
Extreme 15.18
19.09
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.64
Extreme 1.64
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 25/07/2022
Chief Executive Officer 81 01/04/2020
Director of Finance/CFO 48 02/04/2024
Director TitleAgeSince
Chairman 81 01/02/2020
Director/Board Member 48 01/12/2019
Director/Board Member 55 11/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
4/6/26 Buy

Chief Executive Officer

100,000 0.0129%
4/6/26 Buy

Chief Executive Officer

100,000 0.0129%
4/6/26 Buy

Chief Financial Officer

50,000 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
-1.56%+0.32%-24.44%+931.25% 14.07B
-2.59%-5.70%+50.69%+79.01% 70.61B
+0.66%-9.75%+5.10%+52.62% 51.01B
+0.31%-0.14%+8.42%+32.99% 48.1B
+1.42%-1.32%+28.87%+32.88% 42.78B
+1.97%-6.97%+296.31%+698.35% 40.67B
-0.89%-2.97%+7.31%+99.13% 40.3B
-2.13%-1.64%+8.63%+46.15% 30.59B
-2.23%-4.96%+46.01%+6.04% 28.16B
-0.27%-1.13%-5.63%-11.35% 24.36B
Average -0.54%-1.89%+42.13%+196.71% 39.06B
Weighted average by Cap. -0.48%-2.66%+48.39%+148.63%

Financials

2026 *2027 *
Net sales 2.94M 3.88M 3.47M 3.24M 5.54M 371M 5.57M 38.89M 15.22M 191M 14.57M 14.24M 616M 41.88M 55.33M 49.53M 46.18M 78.99M 5.29B 79.49M 555M 217M 2.73B 208M 203M 8.78B
Net income -701M -926M -829M -772M -1.32B -88.48B -1.33B -9.28B -3.63B -45.66B -3.48B -3.4B -147B -743M -982M -879M -819M -1.4B -93.83B -1.41B -9.84B -3.85B -48.42B -3.69B -3.61B -156B
Net Debt -470M -621M -556M -518M -886M -59.35B -892M -6.23B -2.44B -30.63B -2.33B -2.28B -98.55B -200M -264M -237M -221M -377M -25.27B -380M -2.65B -1.04B -13.04B -993M -971M -41.97B
Projected Income Statement - Annual - Summit Therapeutics Inc.
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
13/10/26 USD 17.31 -1.59% 2,893,120
09/10/26 USD 17.59 +2.45% 5,755,325
08/10/26 USD 17.17 -4.35% 6,179,332
07/10/26 USD 17.95 +3.70% 8,175,297
06/10/26 USD 17.31 +0.23% 5,875,829
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Summit Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
13.29GBP
Average target price
22.51GBP
Spread / Average Target
+69.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Summit Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. SMMT Stock